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morbidity mostly associated to lung destruction (O'Sullivan and
Freedman, 2009). This, in turn, is strictly dependent on recurrent
pulmonary infections, with bacteria growing also in bioﬁlms, leading
to an unsatisfactory effect of antibiotics (Ratjen and Döring, 2003).
The CF registry of patients reports an improvement of both patient
survival and quality of life, due to a global care of several aspects of
the disease. Yet, it is an unmet need, hence, the urgency of new antibi-
otics. Recently, Vertex Ph. has introduced in therapy a new potentiator
(a channel gating activator), namely ivacaftor (Kalydeco), whose ef-
fects, are beneﬁcial, to date, for patients exhibiting the G551Dmutation
(Ramsey et al., 2011). Furthermore, the same company has introduced a
combination of lumacaftor (a corrector of defective CFTR folding/
cellular processing, Orkambi) and ivacaftor (Kalydeco) for patients
exhibiting F508del-CFTR, the most common mutation (Wainwright
et al., 2015). The effects of this approach have been discussed in several
papers (see an extensive comment in (Maiuri et al. (2015)). Interesting-
ly, a recent paper reported the effects of Cysteamine in combination
with epigallocatechin gallate, in restoring CFTR function and expression
at plasma membrane in nasal brushing from CF patients, via rescue of
defective autophagy (De Stefano et al., 2014). Noteworthy, cysteamine
has received an Orphan Drug Designation in CF also for its mucolytic
properties. Such an effect is extremely attractive, being thick mucus an
important issue for CF patients. Charrier et al. described the antimicro-
bial, antibioﬁlm and mucoactive properties of cysteamine, either alone
or in combination with recommended antibiotics, a novel mucoactive
antimicrobial and antibioﬁlm agent for the treatment of CF (Charrier
et al., 2014). The authors subsequently reported in the study recently
published and herein discussed, that patients were invited to provide
their sputum, the most being infected with P. aeruginosa (Devereux
et al., 2015). The results of the study prove that daily incubation of
sputum with cysteamine signiﬁcantly decreased the sputum bacterial
load and decreased mucus viscosity. The major limitation regarding
this study is that no patient has been directly administered. Although
cysteamine exhibits also amucolytic activity thatmight help in reaching
the infected pulmonary site, such an issue must be addressed.DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.08.018.
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meaning that it is also difﬁcult to establish a proper mechanism of
action. Finally, the patient mutation type should be taken into account.
The study, however, has a great appeal. In fact, cysteamine is an already
FDA approved drug for another rare disease, cystinosis, and, thus, in
therapy in children. Moreover, side effects have been extensively
documented and cysteamine is a safe drug for cystinosis patients
although it is well known that pharmacokinetic proﬁle and, thus, toler-
ability, might be different in CF patients. Moreover, cysteamine is
endogenously present, although at very low levels, as a consequence
of coenzyme A metabolism (Besouw et al., 2013). The herein cited
study, per se, offers the opportunity to address a new mechanism of
action for cysteamine and to have a novel drug exhibiting multiple
mechanisms of action, being cysteamine an antibiotic,mucolytic and ca-
pable of functionally rescuing misfolded CFTR at plasma membrane.
These results have been developed from independent research groups
and allow to prospectively be positive on the opportunity that cyste-
amine will be also authorized for CF therapy. In conclusion, there is a
strong hope that future studies, carried on with CF patients, will clarify
the antibiotic effects of cysteamine, possibly identifying also a dose
regimen and, if the case, the bacterial strains that can be treated.
Cysteamine, therefore, represents an old drug with several new targets
for CF therapy.
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